Avalyn Pharma’s IPO was oversubscribed, receiving more than ten times the number of orders relative to the shares offered.
The offering’s allocations were highly concentrated, with the ten largest investors acquiring roughly 70% of the total shares.
Bloomberg News, citing sources, reported the IPO was upsized, though specific pricing and size details were not disclosed.